Johnson & Johnson is not alone when it comes to calls for it to spin off its medical device businesses. Novartis has been questioned over the future of its struggling Alcon eye treatments business, and Pfizer and GlaxoSmithKline face pressure to break up, according to the Financial Times.
In a time in which mergers seem all the rage in the medical device industry, it raises the question: Is there such a thing as getting too big and diversified?
